Newsletters

Imagion Biosystems receives AU$3.5 million in R&D tax incentives
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Half-Year Results
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
Shareholder Letter from CEO July 2023
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Quarterly Activity Report and Appendix 4C for 30 June 2023
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
Imagion expands collaboration with Siemens Healthineers to United States
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Imagion set to complete the MagSense® HER2 Phase 1 Study
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
Imagion Announces New CEO
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
2023 AGM Resolution Overview
Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting
Imagion initiates leadership restructuring plan
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
Quarterly Activity Report and Appendix 4C for 31 March 2023
https://youtu.be/8MSNhYapsRI Highlights: Reported positive results of independent review of utility for MagSense® HER2 breast cancer detection Announced plan to advance MagSense® HER2 program to multi-site
[Infographic] MagSense® Imaging Agent Technology Overview
Imagion Biosystems (ASX:IBX) is a biotech company dedicated to improving healthcare through the earlier detection of cancer and other diseases. We are using our proprietary
April 2023 Investor Newsletter
We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April
Pitt Street Research Conducts Market Research Report on Imagion – April 2023
Pitt Street Research has published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the company’s business and investment
Non-renounceable Entitlement Offer – Extension of Closing Date
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company) refers to its announcement titled ‘Non-renounceable Entitlement Offer’ dated 7 March 2023 in relation to the
Imagion to proceed to file an IND for the MagSense HER2 Imaging Agent following FDA feedback
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update
Imagion Chats with 180 Markets on the Future of Cancer Detection
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Cleansing Notice – Entitlement Offer Shares
This notice is given by Imagion Biosystems Limited (the ‘Company’ or ‘IBX’) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (‘Corporations Act’) as modified
Non-renounceable Entitlement Offer
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company), a company dedicated to improving healthcare through the early detection of cancer, today advises that it
Imagion Funding Update
Highlights: Shareholder entitlement offer seeking to raise up to $2.4 million Funding facility of up to $15 million secured with Mercer Street Global Opportunity Fund,
Imagion Secures Growth Funding
Highlights: Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million
Imagion Receives 2nd CSIRO Federal Government Grant for Prostate Cancer Project
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Imagion Biosystems 2022 Annual Report
Imagion Biosystems has released its Annual Report for the year ending 31 December 2022. [See linked documents below] 2022 Research & Development Highlights: March 2022
Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.